<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948022</url>
  </required_header>
  <id_info>
    <org_study_id>centrumtupbebek</org_study_id>
    <nct_id>NCT03948022</nct_id>
  </id_info>
  <brief_title>Luteal Support in Frozen-Thawed Embryo Transfer Cycles</brief_title>
  <official_title>Which Luteal Support in Frozen-Thawed Embryo Transfer Cycles: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrum Clinic IVF Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrum Clinic IVF Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy of 3 different luteal phase support in patients
      undergoing frozen-thawed embryo transfer cycles. Endometrium preparation will be hormone
      replacement in all cycles. Starting from day 11, group 1 will receive 100 mg micronized
      progesterone parenteral daily injections, group 2 will receive 90 mg bioadhesive gel vaginal
      twice daily and group 3 will receive 40 mg oral dydrogesterone daily tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In natural pregnancy, successful implantation and pregnancy necessitates well-functioning
      corpus luteum. Luteal phase support (LPS) is critical in assisted conception cycles
      particularly for replacement frozen embryo transfer cycles owing to lack of corpus luteum. 3
      different LPS options have been suggested:

        -  Progesterone in oil (intramuscular injections) is rapidly absorbed after i.m. injection
           and high progesterone plasma concentrations are reached after approximately 2h. Despite
           satisfactory plasma levels, the possible side-effects of pain and swelling are limiting
           the use.

        -  Vaginal application of progesterone is widely accepted with satisfactory endometrial
           levels and patient convenience. However, increased vaginal discharge and possible
           vaginal irritation are the most common side effects.

        -  Oral administration of synthetic progesterone (dydrogesterone) would offer a convenient
           way of progesterone administration. Better bioavailability than natural progesterone and
           less cost makes dydrogesterone preferable. Also, good quality evidence revealed
           satisfactory outcomes in fresh embryo transfer cycles. However, there is lack of good
           quality evidence for dydrogesterone as a LPS in frozen-thawed cycles.

      The investigator's aim is to compare 3 widely used LPS in frozen-thawed embryo transfer
      cycles.

      Following allocation of the subjects, hormone replacement will be scheduled for the
      endometrial preparation. Briefly; On day 2 of menstrual bleeding, endometrial preparation
      with oral estradiol (E2) (2 mg twice daily) will be initiated. Approximately 10 days after
      initiation of E2 administration, the subject will undergo a transvaginal ultrasound
      examination to assess endometrial development and serum progesterone (P) level will be
      checked. Once the subject achieved a trilaminar endometrium with a thickness of &gt;7 mm with
      serum P levels &lt;1.5 ng/ml, she will start the progesterone treatment to which she will be
      randomized to one of the 3 arms. After 3 days of P treatment along with E2 pills, cleavage
      embryo transfer will be performed. If the subject will receive blastocyst, 5 days of P
      treatment will be scheduled.

      If these criteria were not met at the first evaluation, she will allowed up to 10 additional
      days (20 days total) of estrogen stimulation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2020</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>12th week of pregnancy</time_frame>
    <description>fetal cardiac activity beyond 12th week of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>6th week of pregnancy</time_frame>
    <description>fetal cardiac activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abortion rate</measure>
    <time_frame>during first 10 weeks of gestation</time_frame>
    <description>miscarriage of the pregnancy pregnancy recently confirmed with positive beta hCG blood test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Implantation; Placenta</condition>
  <condition>Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>intramuscular progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 10Mg Tablet (duphaston)</intervention_name>
    <description>40 mg daily oral tablets</description>
    <arm_group_label>oral dydrogesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 50Mg/mL Oil</intervention_name>
    <description>100 mg daily intramuscular injections</description>
    <arm_group_label>intramuscular progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinone 8% Vaginal Gel</intervention_name>
    <description>180 mg daily vaginal gels</description>
    <arm_group_label>vaginal progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  woman aged 20-40 years

          -  Having available blastocyst(s) cryopreserved by vitrification method.

        Exclusion Criteria:

          -  requirement for fresh embryo(s);

          -  presence of any clinically relevant systemic disease contraindicated for assisted
             reproduction or pregnancy

          -  history of more than three failed cycles of IVF

          -  history of recurrent abortions

          -  allergy history for relevant drugs

          -  body mass index of &lt;18 or &gt;38 kg/m2 at screening

          -  current breastfeeding or pregnancy

          -  refusal or inability to comply with the requirements of the protocol for any reason,
             including scheduled clinic visits and laboratory tests

          -  trophectoderm or blastomere biopsy of the blastocyst(s) to be transferred
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emre Pabuccu, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Ufuk University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emre Pabuccu, Assoc. Prof.</last_name>
    <phone>+905324147844</phone>
    <email>emregpabuccu@gmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Devine K, Richter KS, Widra EA, McKeeby JL. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018 Feb;109(2):266-275. doi: 10.1016/j.fertnstert.2017.11.004. Epub 2018 Jan 17.</citation>
    <PMID>29338855</PMID>
  </results_reference>
  <results_reference>
    <citation>Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018 Dec 1;33(12):2212-2221. doi: 10.1093/humrep/dey306.</citation>
    <PMID>30304457</PMID>
  </results_reference>
  <results_reference>
    <citation>Zarei A, Sohail P, Parsanezhad ME, Alborzi S, Samsami A, Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet. 2017 Jan;295(1):239-246. doi: 10.1007/s00404-016-4217-4. Epub 2016 Oct 19.</citation>
    <PMID>27761732</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centrum Clinic IVF Center</investigator_affiliation>
    <investigator_full_name>Emre Göksan Pabuçcu</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>implantation</keyword>
  <keyword>pregnancy</keyword>
  <keyword>abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

